Abstract:Antibodies play a critical role in immunity against enterovirus 71 (EV71). However, how EV71-specific antibodies neutralize infections remains poorly understood. Here we report the working mechanism for a group of three monoclonal antibodies (MAbs) that potently neutralize EV71. We found that these three MAbs (termed D5, H7, and C4, respectively) recognize the same conserved neutralizing epitope within the VP1 GH loop of EV71. Single MAbs in this group, exemplified by D5, could inhibit EV71 infection in cell cultures at both the pre- and postattachment stages in a cell type-independent manner. Specifically, MAb treatment resulted in the blockade of multiple steps of EV71 entry, including virus attachment, internalization, and subsequent uncoating and RNA release. Furthermore, we show that the D5 and C4 antibodies can interfere with EV71 binding to its key receptors, including heparan sulfate, SCARB2, and PSGL-1, thus providing a possible explanation for the observed multi-inhibitory function of the MAbs. Collectively, our study unravels the mechanism of neutralization by a unique group of anti-EV71 MAbs targeting the conserved VP1 GH loop. The findings should enhance our understanding of MAb-mediated immunity against enterovirus infections and accelerate the development of MAb-based anti-EV71 therapeutic drugs. Importance: Enterovirus 71 (EV71) is a major causative agent of hand, foot, and mouth disease (HFMD), which has caused significant morbidities and mortalities in young children. Neither a vaccine nor an antiviral drug is available. Neutralizing antibodies are major protective components in EV71 immunity. Here, we unraveled an unusual mechanism of EV71 neutralization by a group of three neutralizing monoclonal antibodies (MAbs). All of these MAbs bound the same conserved epitope located at the VP1 GH loop of EV71. Interestingly, mechanistic studies showed that single antibodies in this MAb group could block EV71 attachment and internalization during the viral entry process and interfere with EV71 binding to heparan sulfate, SCARB2, and PSGL-1 molecules, which are key receptors involved in different steps of EV71 entry. Our findings greatly enhance the understanding of the interplays among EV71, neutralizing antibodies, and host receptors, which in turn should facilitate the development of an MAb-based anti-EV71 therapy.

Structural basis for the synergistic neutralization of coxsackievirus B1 by a triple-antibody cocktail

Structural Basis for the Immunogenicity of the C-Terminus of VP1 of Echovirus 3 Revealed by the Binding of a Neutralizing Antibody

Molecular mechanism of antibody neutralization of coxsackievirus A16

Potent Neutralizing Monoclonal Antibodies Against Ebola Virus Infection

Identification of Antibodies with Non-overlapping Neutralization Sites That Target Coxsackievirus A16.

A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential.

Discovery and Structural Characterization of a Therapeutic Antibody Against Coxsackievirus A10

Structural Basis for the Synergetic Neutralization of Hepatitis E Virus by Antibody-Antibody Interaction.

Structural Insight into Broadening SARS-CoV-2 Neutralization by an Antibody Cocktail Harboring Both NTD and RBD Potent Antibodies

Development of a Rapid Neutralization Assay for the Detection of Neutralizing Antibodies Against Coxsackievirus B1.

Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody

The structure of CVA10 virus procapsid particle

Evaluation of the Cross-Neutralization Activities Elicited by Coxsackievirus A10 Vaccine Strains.

Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies

Molecular basis of differential receptor usage for naturally occurring CD55-binding and -nonbinding coxsackievirus B3 strains

Broadly therapeutic antibody provides cross-serotype protection against enteroviruses via Fc effector functions and by mimicking SCARB2

A MERS-CoV Antibody Neutralizes a Pre-Emerging Group 2c Bat Coronavirus

Serotype specific epitopes identified by neutralizing antibodies underpin immunogenic differences in Enterovirus B

Poorly Neutralizing Polyclonal Antibody in Vitro Against Coxsackievirus A16 Circulating Strains Can Prevent a Lethal Challenge in Vivo.

Single Neutralizing Monoclonal Antibodies Targeting the VP1 GH Loop of Enterovirus 71 Inhibit both Virus Attachment and Internalization during Viral Entry

A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2